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Abstract
A novel strain of swine influenza A H1N1 has already disseminated
worldwide and has become a major clinical problem for intensive
care units in selected areas. Many regions in the southern
hemisphere are currently struggling to keep up with the influx of
severely affected patients with acute respiratory failure from
primary influenza pneumonia. The northern hemisphere is bracing
for a similar surge of patients over this winter’s influenza season.
This initial report of ventilatory needs for patients with severe
influenza pneumonia in Spanish intensive care units provides a
useful guide of what to expect and how to respond to the
challenge of pandemic influenza.
In the current issue of Critical Care, Rello and colleagues [1]
describe their initial experience with severe swine influenza
pneumonia in Spanish intensive care units (ICUs). The
experience in Spain is similar to that reported from Mexico City
[2] and the US [3], emphasizing an abrupt onset and severe
hypoxemic illness, with acute respiratory failure developing
often in young, previously healthy individuals (the median age
in this study was 36 years). The World Health Organization
declared swine flu a level 6 public health emergency soon
after the emergence and worldwide spread of the influenza
A/Mexico City/2009 (H1N1) virus [4]. This novel swine
influenza strain is highly transmissible person-to-person,
although severe human disease occurs at low frequency. The
currently estimated population mortality rate is 0.1%, but in the
ICU patients reported in the study of Rello and colleagues [1],
it is 18.8%. Although this virus lacks many of the features of
the highly pathogenic influenza A H1N1 1918 strain [5-7] or
the avian H5N1 strain [8,9], it could cause hundreds of
thousands of deaths worldwide if an anticipated population
attack rate of 10% to 50% is confirmed over the next year.
The influenza virus deploys a frontal attack strategy by rapidly
invading the respiratory epithelium of susceptible individuals,
where it induces diffuse necrosis, marked inflammatory
changes, intra-alveolar hemorrhage, and a highly productive
cough. The virus replicates exponentially in human cells and
then is transmitted via respiratory aerosol to other susceptible
human hosts. This process repeats itself throughout the
human populations until such time as sufficient antibodies
and perhaps other innate and acquired immune responses
curtail further spread of the virus. The pathogenicity of this
virus depends on rapid cleavage and activation of its primary
attachment protein hemagglutinin (HA) and efficient release
from cells by its neuraminidase enzyme [5]. Other virulence
factors, seen most prominently in the 1918 and avian H5N1
viruses, include polymerase basic-1 (PB1), PB2, and
nonstructural 1 (NS1) proteins. The PB1-F2 protein primarily
traffics influenza virus to the outer membrane of mitochondria,
inducing cellular energy loss and eventual cell death [10,11].
The NS1 also promotes apoptosis and rapid loss of cell
viability. Fortunately, the current swine flu pandemic strain
lacks a number of these important virulence determinants
[12]. The virus is intrinsically resistant to amantadine and
similar drugs but retains its susceptibility, for the most part, to
the neuraminidase inhibitors oseltamivir and zanamivir.
However, the risk of its developing oseltamivir resistance is
real [13], and this demands caution against the profligate use
of these anti-viral agents.
The current pandemic strain is a quadruple re-assortant virus
with segments of its genome derived from Eurasian swine,
North American swine, avian species, and human influenza
virus strains. The HA from human-adapted strains binds
primarily to sialic acids bound by alpha 2-6 linkages to
galactose found on surface glycoproteins along the
respiratory epithelium. Avian strains prefer alpha 2-3 binding
sites, whereas swine influenza viruses usually bind to either
alpha 2-3 or alpha 2-6 sialic acid-galactose linkages. This
Commentary
Coming soon to an ICU near you: severe pandemic influenza in
ICU patients in Spain
Steven M Opal
Warren Alpert Medical School of Brown University, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, 
RI 02860, USA
Corresponding author: Steven M Opal, steven_opal@brown.edu
Published: 21 October 2009 Critical Care 2009, 13:196 (doi:10.1186/cc8112)
This article is online at http://ccforum.com/content/13/5/196
© 2009 BioMed Central Ltd
See related research by Rello et al., http://ccforum.com/content/13/5/R148
HA = hemagglutinin; ICU = intensive care unit; NS1 = nonstructural 1; PB = polymerase basic.Critical Care    Vol 13 No 5 Opal
Page 2 of 3
(page number not for citation purposes)
probably explains why swine are important as intermediate
hosts for novel pandemic flu strains that periodically affect
human populations [5].
In their report, Rello and colleagues [1] point out a
disproportionately high frequency of severe pneumonia in
pregnant women and obese patients. The risk of severe
influenza in pregnant women during pandemics has been well
known for decades [14]. Less well characterized is the
increased risk of severe influenza pneumonia in obese
patients. This observation might not be mere coincidence;
obese patients are more difficult to ventilate due to chest wall
restriction, and adipocytes are immunologically active cells
with fat tissue replete with macrophages [15]. Adipose tissue
generates proinflammatory cytokines and this may conspire
with a systemic inflammatory response from influenza
pneumonia to increase severity and mortality rates in obese
patients. The events that have taken place in Spanish ICUs
are likely to be repeated many times over in ICUs throughout
the world.
Pandemic influenza generally occurs only once or twice during
a professional career. How well, or how poorly, we respond as
a global community will be judged for decades to come. How
well prepared are we? Will the new H1N1 vaccines become
available in time to protect susceptible human populations?
Will supplies of anti-viral agents be sufficient and be equitably
distributed throughout the world? The evidence so far
suggests that there will be substantial shortfalls in supplies of
both [10,11,16], and these shortfalls will likely cause severe
difficulties in developing countries [17].
Could we use our current knowledge of the immunology and
host response to influenza to devise an effective approach to
help patients with severe pneumonia? The pathologic series
of events leading to death from influenza likely has hereditary
[18], environmental [19], and inflammatory [7,9] components.
Is there too much inflammation in primary influenza pneumonia,
or is there insufficient inflammation resulting in poor viral
clearance? How many of the fatalities from influenza
pneumonia are attributable to secondary bacterial pneumonia?
Individual variation in the host response to influenza virus
infection is probably an important determinant of ultimate
outcome. Could we intelligently determine specific patient
needs and intervene appropriately in severely afflicted patients?
A number of currently available agents on the market might
provide some benefit in managing severe, primary, influenza
pneumonia [10,11,20]. Would corticosteroid administration
benefit selected patients or worsen viral shedding and
mortality in severe influenza? Should we give immuno-
adjuvants or immune suppressive agents in combination with
anti-viral agents? These clinical questions need to be studied
expeditiously and conclusively answered. Will we move
forward together with a rapidly expanding, evidence-based
approach to understanding influenza and its optimal manage-
ment and be willing to share our knowledge and financial
assets equitably between richer and poorer nations? As this
pandemic evolves, the answers to these and other questions
will become starkly evident within the next 12 months.
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